Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Zelda Therapeutics — Investor Presentation (November 2016)
22 slides from Zelira Therapeutics's investor presentation, Nov 22, 2016
Slide 1: Investor Presentation Nov 2016
For personal use only Investor Presentation Nov 2016 www.zeldatherapeutics.com
Slide 2: Disclaimer and Important Notice
Disclaimer and Important Notice 2 Disclaimer For personal use only This presentation has been prepared by Zelda Therapeutics Pty Ltd ACN 607 538 876 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in
Slide 3: Company Overview
Company Overview 3 For personal use only Zelda Therapeutics (“Zelda’s”) is a private Californian-founded biotechnology company focused on medical cannabis therapies with a strong Australian connection Targeting clinical efficacy trials at leading clinical research organisations Leveraging an exi
Slide 4: Corporate Structure
Corporate Structure 4 For personal use only Overview Relisted on ASX Nov 2016 ASX: ZLD Top 20 shareholders own 60% of the stock (50% of the shares are escrowed) Issued 160m shares @ 2.5c to raise $4m Market Capitalization - $16.7m (@2.5c) Shares on issue – 670m Options on issue – 40m Cash at bank ap
Slide 5: Use of Funds
Use of Funds 5 For personal use only Fund business development Fund planned clinical Fund research and pre-clinical trials in Insomnia, trials in cancer to partner and license products cancer and dermatology indications General working capital 21% Listed company overheads 6% 41% Clinical trial costs
Slide 6: Board & Management Team
Board & Management Team 6 For personal use only Harry Karelis Mara Gordon Jason Peterson Dr Stewart Washer Founder & Executive Founder & Director Founder & Director Founder & Director Chairman Mara is the co- Jason is a Director, Stewart has 25 years Harry is the founder founder of Aunt major shareh
Slide 7: World-leading Scientific Advisory Board
World-leading Scientific Advisory Board 7 For personal use only Professor Manuel Dr Cristina Sánchez Dr Joe Goldstrich Dr Noah Federman Guzmán Assistant Professor at Distinguished clinical Highly respected Full Professor of Complutense career in preventive paediatric clinical Biochemistry and Univer
Slide 8: How Does Medical Cannabis Work?
How Does Medical Cannabis Work? 8 For personal use only Different medical Cannabis contains Cannabinoids bind to effects can be more than 85 types of The natural receptors in the brain achieved by targeting cannabinoids, the endocannabinoid and body, mimicking different receptors, chemical compounds
Slide 9: Structural Drivers of Rapid Change
Structural Drivers of Rapid Change 9 use only Medical cannabis is becoming recognised worldwide as a natural and effective medicine to treat a growing number of diseases and conditions Evidence based shift, driven by patients and high profile medical figures Compelling clinical Use is regulated
Slide 10: Whole Spectrum Extracts More Effective
Whole Spectrum Extracts More Effective 10 For personal use only Whole spectrum cannabis extracts include most of the natural cannabinoids and active compounds from the plant Chemically synthesized cannabis medicines and single compounds have been shown to be less effective and have been available fo
Slide 11: Broad Medical Opportunity
Broad Medical Opportunity 11 A broad range of medical indications For personal use only have been shown to be alleviated by medical cannabis Key indications for use of medical cannabis: Known Uses New Uses Spasticity in Multiple Sclerosis Dermatology Post Traumatic Stress Disorder Insomnia
Slide 12: Cultivation and Production
Cultivation and Production 12 For personal use only The selection and cultivation of medical cannabis is undertaken under stringent controls to ensure the quality is clinical grade quality and cannabinoid content is consistent Zelda’s will obtain its source material and medicinal extracts throug
Slide 13: Leadership Position Through Aunt Zelda's
Leadership Position Through Aunt Zelda’s 13 For personal use only Time/Cost Advantage via partnership - straight to clinical trials About Aunt Zelda’s Exclusive access to patient data, A pioneering California-based group supplying protocols and formulations from customized medical extracts to regi
Slide 14: Case Study – Chico Ryder
Case Study – Chico Ryder 14 For personal use only • 11 Year old child diagnosed with rhabdomyosarcoma in 2012 • Doctors said surgery was too risky and he would need chemotherapy and radiation • Doctors prescribed Marinol, to help with the side effects of the chemo and radiation treatments During Tre
Slide 15: Multiple Therapeutics and Applications
Multiple Multiple Therapeutics Therapeutics and and Applications Applications 15 For personal use only Strategic focus on the development of treatments for skin conditions, cancer and insomnia Relatively low cost, short duration trials in high value niche indications for max value Pipeline: • Insomn
Slide 16: Large Patient Markets
Large Multiple Patient Therapeutics Markets and Applications 16 For personal use only Wound Care Global wound care market expected to reach US$18.3 billion by 2019 CAGR of 3.2% Source: MarketsandMarkets Breast Cancer • Over 1.5 million patients in 2010 • Expected to exceed $13 billion by 2020 CAGR o
Slide 17: Highly Defensive Products
Highly Multiple Defensive Therapeutics Products and Applications 17 For personal use only FDA guarantees seven years of market exclusivity for specific formulations of various cannabinoids or their derivatives for treatment of rare diseases1. Zelda has patents pending over formulations and uses
Slide 18: Strong Partnerships
Strong Multiple Partnerships Therapeutics and Applications 18 For personal use only Working with world leaders in cannabis medicine Exclusive patient data access agreement in place with Aunt Zelda’s includes formulations & protocols Manufacturing agreement in place with AusCann, an Australian compan
Slide 19: Clear Commercialisation Strategy
Clear Multiple Commercialisation Therapeutics and Strategy Applications 19 Conduct studies with key For personal use only research institutions and specialist clinical research organisations (CROs) Third party- licensing or Design key pre- partner with clinical and clinical Up-front REVENUE Royaltie
Slide 20: Competitive Landscape
Competitive Multiple Therapeutics Landscapeand Applications 20 For personal use only Marketed/Trial Existing Multiple Multiple Company Lead Product/s status patient data Indications Formulations Dermatology Zelda Therapeutics Clinical trial (US $13m market cap) Insomnia ready ✓ ✓ ✓ Cancer Sativex GW
Slide 21: High Activity Newsflow and Pipeline
High Multiple Activity Therapeutics Newsflowand Pipeline Applications 21 For personal use only Initial data from pre-clinical research in human breast cancer via Complutense University Madrid Pre-clinical research in other cancers Clinical trials Insomnia Eczema Others to be announced 20
Slide 22: Summary
Summary Multiple Therapeutics and Applications 22 For personal use only Diverse worldwide Acceleration to efficacy Focus on large and Clear strategy to out- opportunity opening up clinical trials, through growing dermatology, license at end of phase 2 Aunt Zelda’s patient data insomnia and cancer wi
Zelda Therapeutics — Investor Presentation (November 2016) on 6ix